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Abstract   
Objective: Key augmented processes in atherosclerosis have been identified, whereas less 
is known about downregulated pathways. Here we applied a systems biology approach to 
examine suppressed molecular signatures, with the hypothesis that they may provide insight 
into mechanisms contributing to plaque stability.  
Approach and Results: ‘Muscle contraction’, ‘muscle development’ and ‘actin cytoskeleton’ 
were the most downregulated pathways (FDR=6.99e-21, 1.66e-6, 2.54e-10 respectively) in 
microarrays from human carotid plaques (n=177) vs. healthy arteries (n=15). In addition to 
typical SMC markers, these pathways also encompassed cytoskeleton-related genes 
previously not associated with atherosclerosis. SYNPO2, SYNM, LMOD1, PDLIM7, and PLN 
expression positively correlated to typical SMC markers in plaques (Pearson r>0.6, p<0.0001) 
and in rat intimal hyperplasia (r>0.8, p<0.0001). By immunohistochemistry, the proteins were 
expressed in SMCs in normal vessels, but largely absent in human plaques and intimal 
hyperplasia. Subcellularly, most proteins localised to the cytoskeleton in cultured SMCs and 
were regulated by active enhancer histone modification H3K27ac by ChIP-seq. Functionally, 
the genes were downregulated by PDGFB and IFNg, exposure to shear flow stress and 
oxLDL loading. Genetic variants in PDLIM7, PLN and SYNPO2 loci associated with 
progression of carotid intima-media thickness in high-risk subjects without symptoms of 
cardiovascular disease (n=3378). By eQTL, rs11746443 also associated with PDLIM7 
expression in plaques. Mechanistically, silencing of PDLIM7 in vitro led to downregulation of 
SMC markers and disruption of the actin cytoskeleton, decreased cell spreading and 
increased proliferation.   
Conclusions: We identified a panel of genes that reflect the altered phenotype of SMCs in 
vascular disease and could be early sensitive markers of SMC dedifferentiation. 
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Abbreviations 
AF- amaurosis fugax 
AHA- American Heart Association 
AS-asymptomatic 
BiKE- Biobank of Karolinska Endarterectomies 
CEA- carotid endarterectomy 
CP- carotid plaque 
CHip- chromatin immunoprecipitation 
CNN- calponin 
cIMT- carotid intima-media thickness 
ECM- extracellular matrix 
LMOD1-leiomodin 1 
GEO- Gene Expression Omnibus 
IHC- immunohistochemistry 
IFL- immunofluorescence 
MS- minor stroke 
MYOCD- myocardin 
MYH11- myosin heavy chain 11 
NA- normal artery 
NCA- normal carotid artery 
PCNA- proliferating cell nuclear antigen  
PDGF- platelet derived growth factor 
PLN- phospholamban 
PDLIM7- PDZ and LIM domain containing 7 
RNAseq- RNA sequencing 
qPCR- quantitative polymerase chain reaction 
FDR- false discovery rate 
S- symptomatic 
SMC- smooth muscle cell 
SMA- smooth muscle actin 
SYNM- synemin 
SYNPO2- synaptopodin 2 
TIA- transitory ischemic attack 
TAGLN- transgelin 
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Introduction 
Unstable atherosclerosis in the carotid bifurcation is a common cause of stroke, and 
guidelines recommend treatment with stroke-preventive carotid endarterectomy (CEA) in 
patients with signs of cerebral embolism1. Stable, asymptomatic (AS) carotid lesions are 
generally rich in extracellular matrix (ECM) and smooth muscle cells (SMCs), whereas 
unstable (symptomatic, S) plaques contain abundant inflammatory cells and a thin fibrous 
cap prone to rupture2. Inflammation, cytokines, mitogens, ECM degradation and altered cell-
matrix interactions have been associated with intraplaque processes in atherogenesis which 
promote activation of contractile SMCs in the media into a secretory and replicating 
phenotype that engage in intimal remodeling and formation of the fibrous cap.  
Contractile SMCs are distinguished from other cell types by expression of a unique repertoire 
of markers including Smooth Muscle Actin (SMA, ACTA2), Calponin (CNN1), Transgelin 
(TAGLN), Myocardin (MYOCD) and Myosin Heavy Chain 11 (MYH11), mostly associated 
with the acto-myosin cytoskeleton. These genes are downregulated in activated SMCs and 
may be undetectable using traditional immunohistochemical staining methods3, 4. However, it 
is unclear whether altered expression of these genes takes place concomitantly or 
successively during phenotypic modulation. This problem is notable in atherosclerotic lesions 
where SMA positive (SMA+) cells define several distinct regions and can be found in the 
necrotic core and the fibrous cap (Figure 1A). Recently, SMC transdifferentiation into CD68+ 
macrophage-like cells has been demonstrated in atherosclerosis5, 6 which further emphasizes 
the complexity in characterizing SMC phenotypes in vascular disease. Apart from 
atherogenesis, activation of SMCs also dominates in healing reactions aimed to repair the 
vessel after injury, healing of ruptured atheromas7, restenosis after arterial interventions8 and 
in the failure of vein grafts and dialysis fistulas9.  
Understanding the molecular and cellular processes that convert asymptomatic plaques into 
symptomatic ones may facilitate the development of preventive pharmacotherapy with 
unprecedented impact on cardiovascular mortality and morbidity. For this purpose, intensive 
efforts have been dedicated to the identification of suitable targets through analysis of 
augmented pathways and molecules in vulnerable lesions10, 11. In contrast, less is known 
about pathways that are inhibited in atherogenesis and in the process of plaque instability. 
Since identification of such inher nt functional changes within the vessel wall may give clues 
to therapies that can sustain arterial resistance to atherogenic stimuli or improve stability of 
established complex lesions, studies of downregulated genes and suppressed pathways may 
be equally important12. Identification of ultimately translatable target molecules is bound to be 
more successful when generated directly from human disease, followed by clinical and 
experimental exploration. 
Recently we performed a comprehensive transcriptomic analysis of late-stage human carotid 
atherosclerosis based on defined clinical patient phenotypes13. Our findings confirmed a 
central role for lipid accumulation, inflammation and proteases in plaque instability, and 
highlighted haemoglobin metabolism and bone resorption as important enriched pathways in 
plaques. Here, we instead analysed downregulated molecular signatures in carotid plaques 
by applying an integrative framework based on collaboration among three large human 
biobanks: initial discoveries were made using material from the Biobank of Karolinska 
Endarterectomies (BiKE, n=177 plaques from end-stage atherosclerosis patients and n=15 
macroscopically healthy, normal arteries); data was further validated using atheroprogression 
samples from the SOKRATES biobank (n=28 patients tissues); and genetic analyses were 
performed in the IMPROVE cohort (n=3378 high-risk patients without symptoms or signs of 
cardiovascular disease). We found that SMC-related functional categories were the most 
significantly affected in plaques and identified a set of downregulated SMC-related genes 
previously poorly studied in vascular disease. Temporal changes in the expression of these 
genes were followed in the rat carotid injury model and in primary SMCs in vitro in 
comparison with typical SMC markers. Genetic association with progression of carotid 
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intima-media thickness (cIMT) as a surrogate marker of atherosclerosis, was investigated in 
the large cohort of high-risk subjects and mechanistic studies were performed for one of 
these genes in vitro. We report a panel of novel SMC markers that are suppressed in 
vascular disease in humans and may reflect the altered phenotype of SMCs during vascular 
remodelling.  
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Material and Methods 
Material and Metods are available in the online-only Data Supplement.  
Results 
Genes and pathways associated with SMCs are repressed in atherosclerosis 
Pathways associated with ‘muscle contraction’, ‘muscle development’ and ‘actin cytoskeleton’ 
were the most significantly downregulated in microarrays comparing late-stage human 
carotid plaques (CP) vs. normal arteries (NA) as well as in plaques extracted from 
symptomatic vs. asymptomatic patients (e.g. in CP vs. NA comparison FDR=6.99e-21, 
1.66e-6 and 2.54e-10 respectively, Supplementary Table I). Genes clustered in these 
categories were the typical markers of SMCs and acto-myosin cytoskeleton (Supplementary 
Fig IA). Among the most significantly downregulated genes appeared several whose function 
in SMCs was previously unexplored in the context of atherosclerosis: LMOD1 (Leiomodin 1), 
SYNPO2 (Synaptopodin 2), PLN (Phospholamban), PDLIM7 (PDZ and LIM domain 
containing 7) and SYNM (Synemin). By constructing functional networks from their extended 
protein-protein interactions and expression profiles across tissues 14-16, we noted that these 
genes were co-expressed with actin and microtubule markers (Figure 1B) and some of them 
also co-interacted with the cytoskeleton based on available public data (i.e. PDLIM7, SYNM, 
LMOD1 and SYNPO2; Supplementary Figure IB). Strong downregulation of these transcripts 
was found in two non-overlapping microarray datasets comparing carotid plaques to normal 
arteries (n=127 CP vs. n=10 NA and n=50 CP vs. n=5 NA, p<0.0001 for most transcripts) 
and downregulation was also noted in plaques from symptomatic vs. asymptomatic patients 
(n=87 S vs 40 AS, p<0.01) (Figure 1C, full list in Supplementary Table II). Moreover, the 
protein levels were also lower in plaques from S vs. AS patients, as determined by mass 
spectrometry (n=9 S vs 9 AS, Supplementary Figure II). Additionaly, a trend towards 
downregulation of these genes was observed in publicly available microarray datasets 
comparing human carotid plaques (n=12) vs. normal arteries (n=9)10 and carotid plaques 
(n=32) vs. matched adjacent tissue (GSE43292). Strong positive correlations were seen 
between mRNA expression of LMOD1, SYNPO2, PLN, PDLIM7 and SYNM in carotid 
plaques and typical SMC markers such as ACTA2, MYH11, CNN1, MYOCD (Pearson r>0.6, 
p<0.0001, representative examples in Figure 1D, full data in Supplementary Table III). 
Similarly, strong correlations between corresponding protein levels, as determined by mass 
spectrometry, were also demonstrated (Pearson r>0.8, p<0.0001, Supplementary Table III). 
To further investigate the association of the selected genes with SMCs, we analyzed a 
publicly available microarray dataset (GSE23303) comparing microdissected SMC-rich 
subintimal regions of carotid plaques with macrophage-rich regions from the necrotic core. 
We found that mRNA levels of these genes were strongly downregulated in macrophage-rich 
compared with SMC-rich regions, while no significant difference was seen in this comparison 
for ACTA2 (Supplementary Table II).  
To experimentally corroborate our findings from human plaques, we analyzed the expression 
of the selected genes in an inducible plaque rupture model on ApoE background, where mice 
present atherothombotic events and morphological signs of plaque instability 17. Expression 
of all 5 genes of interest was strongly downregulated in ligated vs. non-ligated arteries (i.e. 
mRNA mean fold change= -114, p<0.0001 for Synpo2; fold change= -45, p<0.0001 for 
Lmod1), and marginally also in comparison between ruptured vs. stable plaques, thus 
replicating results from the human datasets (Supplementary Table IV).  
Collectively, these results demonstrated that we have identified a set of previously poorly 
characterised genes through transcriptomic profiling of late-stage human atherosclerosis, 
likely associated with loss of contractile SMC features in the disease.  
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LMOD1, SYNPO2, PDLIM7, SYNM and PLN are expressed by SMCs  
The localisation of selected genes and proteins in normal human vessels and carotid plaques 
was performed by in situ RNA hybridization and immunohistochemistry and compared with 
typical SMC markers such as MYH11, CNN1 and SMA, including proliferating cell nuclear 
antigen (PCNA) as a marker of cell proliferation. By immunohistochemistry, MYH11, 
considered to be an early marker of phenotypic changes in SMCs3, was only detected in 
PCNA- SMCs in normal carotid artery media but was absent in late-stage plaques, while 
CNN1 was detectable in the normal artery as well as in subintimal SMA+/PCNA- cells and in 
SMA+ cells in the fibrous cap of carotid plaques (Figure 2A). By co-immunostaining, SMA, 
LMOD1, SYNPO2, PDLIM7, SYNM and PLN were all abundantly expressed in SMCs in 
normal arteries (carotid artery stainings shown in Figure 2B). The stainings appeared mostly 
cytosolic, except in the case of PLN, which exhibited nuclear staining. In late-stage plaques, 
PDLIM7 was present in subintimal SMCs and weak expression was also detected in stellate-
shaped SMA+ cells in the fibrous cap. SYNM showed a similar staining pattern in subintimal 
SMCs but was absent from the fibrous cap. SYNPO2, LMOD1 and PLN were not detectable 
in these plaques by immunohistochemistry. RNA transcripts of MYH11, CNN1, ACTA2 and 
selected genes were all detectable in the normal artery media and to a lesser extent also in 
cells with elongated nuclei in the fibrous cap (except PLN, Supplementary Figure III).  
We further investigated the expression of these genes during atheroprogression, using 
human aortic lesions from different stages of disease graded according to the modified 
American Heart Association criteria18, ranging from adaptive intimal thickening and xantomas 
(stages I and II), via pathological intimal thickening (stage III) to early and thin-cap 
fibroatheromas (stages IV and V). In these lesions, SMA and CNN1 were detectable in 
SMCs from early stages to advanced lesions, while MYH11 as expected, was absent from 
PCNA+ SMCs already at stage I (Supplementary Figure IV). LMOD1 and SYNPO2 were 
mostly absent already from stage I, PLN was not detectable from stage III, whereas SYNM 
and PDLIM7 were present in subintimal SMCs but sparsely in cells that build the fibrous cap 
from stage III. Interestingly, in human intimal hyperplasia, we observed the reappearance of 
both typical SMC markers and the selected genes in SMA+/PCNA- areas (Figure 2). 
Abundant signal was observed for CNN1 as w ll as for PDLIM7 and SYNM, while LMOD1, 
SYNPO2 and PLN were sparsely present. Our results confirm that these genes localise to 
quiescent SMCs in normal artery media and undergo various degrees of downregulation at 
both transcript and protein levels in activated SMA+ cells of lesions, with reappearance in 
mature intimal hyperplasia. Of note, these proteins were also detected in SMA+ cells in 
several other smooth muscle-rich tissues (Supplementary Figure V).  
Lmod1, Synpo2, Pdlim7, Synm and Pln are downregulated early in reponse to 
experimental vascular injury but reappear in mature neointima  
Time-dependent alterations in expression of SMC markers were examined by transcriptomic 
analysis from rat carotid arteries after balloon injury (Figure 3). Typical SMC genes along 
with Lmod1, Synpo2, Pdlim7, Synm and Pln showed similar gene expression profiles with 
gradual downregulation in the early phases after injury, but upregulation after 2-12 weeks in 
the mature neointima. Expression correlations of Lmod1, Synpo2, Pln, Pdlim7 and Synm with 
typical SMC markers in this model were strongly positive (mostly Pearson r>0.8, p<0.0001, 
Figure 3C, Supplementary Table III) and negative with cytokines such as Pdgfb, Igf1 and 
Tgfb1 (Figure 3C). By IHC, we observed loss of CNN1 from PCNA+ SMC layers closer to the 
lumen, while the staining was still present in deeper medial layers at day 5 and again 
abundant in the mature intima with reduced PCNA staining 12 weeks after injury (Figure 4A). 
Staining for LMOD1, SYNPO2, PDLIM7, SYNM and PLN was absent at day 5 with gradual 
reappearance in medial SMCs in tissues with pronounced intimal hyperplasia 12 weeks after 
injury (Figure 4B). No similar changes in gene expression patterns were found in 
contralateral uninjured arteries (Supplementary Figure VI). These analyses indicated that 
downregulation of Lmod1, Synpo2, Pln, Pdlim7 and Synm might functionally relate to SMC 
activation in response to injury.   
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LMOD1, SYNPO2, SYNM, PDLIM7 and PLN localise mostly to actin-cytoskeleton in 
SMCs and relate to phenotypic changes in vitro  
To address the expression of the selected genes during the process of SMC phenotypic 
modulation, rat aortic SMCs were isolated by collagenase digestion, seeded on fibronectin 
and cultured in serum-free medium or medium supplemented with PDGFBB for 7 days19. 
Directly upon isolation (day 0), almost 90% of the cells were SMA+ by flow cytometry, 
although lower SMA levels in a subgroup of cells were detectable (Figure 5A). After 7 days, 
95% of the population cultured in serum-free medium uniformly expressed higher levels of 
SMA, while cells stimulated with PDGFBB showed presence of two subpopulations of which 
one expressed lower signal for SMA (totally 77% SMA+ cells, Figure 5A, detailed analysis 
shown in Supplementary Figure VII). By qPCR, mRNA levels of Acta2, Myocd and Myh11 as 
well as Lmod1, Synpo2, Pdlim7, Synm and Pln strongly decreased from day 1 to day 3 in 
culture, but on day 5 and 7 the expression of most of these genes (except Synm) gradually 
increased. At each reference time-point, cells cultured in the presence of PDGFBB showed 
downregulation of the target genes compared to cells in serum-free medium (Figure 5B). By 
RNA-sequencing, downregulation of LMOD1, SYNPO2, PDLIM7, SYNM and PLN was also 
observed in low-passage human SMCs cultured in serum-supplemented (de-differentiation 
condition) vs. serum-free medium (Supplementary Table V).  
By ChIP-sequencing, we observed that all these genes were under the regulation of active 
enhancer histone modification H3K27ac (Supplementary Table VI). Prediction of putative 
binding motifs in genomic sequences using MSigDB software searching a span of ±2000 
basepairs around the transcription start site, we found 3 CArG motifs present upstream of 
human PDLIM7 (at positions +650, +654, +667) and one SRF binding site in the PLN gene, 
but no such motifs were found in either SYNPO2, LMOD1 or SYNM in this analysis. Another 
prediction program MotifMap, searching a wider region within 8000 basepairs around the 
transcription start, suggested regulation by several other transcription factors previously 
associated with SMCs or control of cell proliferation. Here, TEF1 and MAFA were predicted 
to regulate LMOD1; AP1 and SRF to regulate PDLIM7; TEF1 and SRF to regulate PLN; and 
CTCF and NEUROD to control SYNPO2 (full list in Supplementary Table VII).  
Subcellular localization of SMC markers was also assessed in low-passage human SMCs 
(Figure 5C, additional images shown in Supplementary Figure VIII). CNN1, PDLIM7 and 
SYNPO2 were localized to the actin cytoskeleton by overlap with phalloidin staining; SYNM 
localized to cellular filopodia and to the cortical cytoskeleton; PLN exhibited nuclear staining 
while MYH11 and LMOD1 could not be detected in these cells. Taken together, our data 
confirm that SMCs maintain phenotypic plasticity in vitro and show that the expression 
changes and cytoskeletal localization of the selected genes strongly correlate with those of 
typical SMC markers in vitro, as initially observed in situ.  
Downregulation of LMOD1, SYNPO2, SYNM, PDLIM7 and PLN in response to 
inflammatory-, hemodynamic- and lipid stimuli 
Next, we explored processes relevant in the environment of an atherosclerotic lesion that 
may influence expression of the genes identified in our study. The expression of standard 
SMC markers as well as LMOD1, SYNPO2, SYNM, PDLIM7 and PLN was rapidly 
downregulated in human SMCs in vitro by stimulation with IFNg (Figure 6A). Downregulation 
of all genes was observed within 24h of IFNg treatment, whereas expression of PLN, 
PDLIM7, SYNM and SYNPO2 was suppressed already after 2h. These genes were also 
downregulated in human SMCs after 48-72hrs stimulation with oxLDL (in particular SYNPO2, 
LMOD1 and PLN, Figure 6B), which was validated by analyzing a public microarray dataset 
comparing cholesterol-loaded primary mouse aortic SMCs with baseline controls (GSE47744, 
Supplementary Figure IX)20. In this model, the typical SMC markers ACTA2 and CNN1 were 
also downregulated, whereas the macrophage marker CD68 was upregulated. Finally, we 
analyzed expression of these genes in an in vitro model of SMC exposure to laminar shear 
stress, mimicking the exposure of the injured vessel surface to the hemodynamic forces of 
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the flowing blood21. In microarrays comparing shear stress vs. static conditions, we have 
previously observed apoptosis as an enriched pathway through activation of CASP3 (dataset 
accession nr GSE19909) and all genes (as well as other typical SMC markers) were also 
found to be downregulated in this model (Figure 6C).  
Collectively, our results demonstrate that downregulation of LMOD1, SYNPO2, SYNM, 
PDLIM7 and PLN along with standard SMC markers, functionally relates to clinical symptoms 
of plaque instability, vascular injury, as well as to key molecular processes in atherosclerosis 
such as apoptosis, shear stress, inflammatory stimuli and lipid-uptake. 
Polymorphisms in PDLIM7, SYNPO2 and PLN associate with surrogate markers of 
atherosclerosis  
In order to investigate the involvement of LMOD1, SYNPO2, PDLIM7, SYNM and PLN in 
early processes shown to be predictive of carotid and coronary artery disease in humans, we 
examined the association of genetic variants in these loci with severity and rate of cIMT 
progression. Several variants in the PDLIM7, SYNPO2 and PLN genomic regions were found 
to be associated with cIMT phenotypes in a large cohort of high-risk subjects (n=3378, 
IMPROVE)22 after adjustment for age, gender and population stratification (Supplementary 
Table VIII). Variants rs11746443 and rs35716097 (PDLIM7) associated with the maximum 
thickness of the common carotid artery (p=0.002) and the fastest cIMT progression 
(p=0.0009, p=0.002, respectively), and variants rs67456868 (PLN) and rs4833611 (SYNPO2) 
were associated with the maximum common carotid artery thickness (p=0.00004, p=0.0007, 
respectively). Full functional information obtained from Haploreg for these variants is 
presented in Supplementary Tables IX and X. The SYNPO2 variant rs4833611 was located 
in the intronic region of the USP53 gene and by eQTL analyses marginally linked to SYNPO2 
(p=0.09) and USP53 (p=0.02) gene expression in plaques. Of particular interest, PDLIM7 
variant rs35716097 was predicted to constitute a putative binding site for the HNF4A 
transcription factor. The other PDLIM7 variant rs11746443 was localised in the genomic 
region of RGS14 and predicted to constitute the binding site for the HEY1 transcription factor, 
while its proxy (rs4075958, Rsquared=0.927, Dprime=0.963) was mapped within the putative 
binding site for the ETS1 transcription factor. By eQTL analysis in plaques, rs4075958 was 
found to be significantly associated with the expression of both PDLIM7 and RGS14 
(p=0.007 and p=0.0002 respectively, Figures 7A and 7B) and the expression levels of both 
genes were strongly correlated (Pearson r=0.61, p<0.0001) (Figure 7C). PDLIM7 and 
RGS14 also appeared to be linked in a protein interaction network via actin cytoskeleton and 
markers of differentiated SMCs, SMTN and CNN2 (Figure 7D). Altogether, our results 
underline the possiblity that genetic variants associated with PDLIM7 may be causal to 
altered intima-media phenotypes and predisposition to atherosclerosis.  
Silencing of PDLIM7 leads to downregulation of other SMC markers and increased 
SMC proliferation  
Of the five genes that were identified, PDLIM7 emerged as one of the hub genes in the 
interaction network with other signature genes in atherosclerosis13. Since PDLIM7 was 
causally implicated in atherogenesis at the genetic level, localised to SMC actin cytoskeleton 
and in addition, interconnected with other cytoskeletal proteins, we decided to 
mechanistically investigate its role in SMCs. Silencing PDLIM7 expression in human carotid 
SMCs in vitro, resulted in downregulation of other SMC markers (ACTA2, MYH11, LMOD1, 
PLN and particularly SYNPO2 by approximately 70% on the mRNA level). Cell adhesion and 
spreading on fibronectin were defective compared with controls, and proliferation was 
significantly increased in these cells as evaluated by BrdU incorporation (p<0.0001; Figure 8, 
Supplementary Figure X). These findings add mechanistic support to the notion that PDLIM7 
is an important structural molecule in the regulation of SMC phenotype. 
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Discussion 
A large biobank of carotid endarterectomies obtained from patients undergoing surgery for 
symptomatic or asymptomatic carotid stenosis was used to identify suppressed processes in 
atherosclerosis. We found molecular pathways related to SMC function and phenotype but 
also a panel of genes (SYNPO2, SYNM, LMOD1, PDLIM7, PLN) previously not associated 
with vascular disease, not only to be the most repressed in end-stage atherosclerosis but 
also in relation to clinical symptoms of plaque instability, both on the transcriptomic and 
proteomic level. We hypothesized that some of these genes may show early expression 
variations and demarcate the initiation of SMCs phenotypic switching. Most of these genes 
were linked to the SMC cytoskeleton, downregulated during neointima formation after rat 
carotid balloon injury, and polymorphisms in PDLIM7, PLN and SYNPO2 genomic regions 
were associated with cIMT phenotypes in high-risk subjects. In addition, expression of these 
genes was sensitive to predominant processes in the atherosclerotic lesion such as 
apoptosis, inflammation, hemodynamic stress, and lipid exposure. We propose that these 
SMC genes may improve definition of the phenotypic state of these cells in vascular disease 
and may be further explored in relation to the capacity of SMCs to contribute to plaque 
stabilization.  
Previously, transition of SMCs from a contractile and quiescent phenotype into synthetic, 
matrix-producing and replicating cells has been widely accepted as a central feature in early 
atherogenesis and an essential part of lesion stability and repair. This process, where the 
typical contractile features of SMCs are lost, represents an example of disturbed vessel wall 
homeostasis in disease progression. However, it has become evident that these conclusions 
oversimplify the complexity of SMC function in vascular disease and that these phenotypes 
probably represent the extremes of a spectrum of intermediate phenotypes that may to 
various extents coexist in the vessel wall, as dictated by exposure to environmental cues 
affecting gene expression patterns23. Recent studies have presented strong evidence that 
SMCs and macrophages can activate the same genes by demonstrating that 50% of foam 
cells within advanced human coronary artery lesions express the SMC marker SMA besides 
the macrophage marker CD68, while lineage tracing in mice confirmed that up to 80% of the 
lesion cells (including mesenchymal stem cells and macrophage-like cells) are SMC-derived5, 
6. Here, we demonstrated that a number of SMC markers remain repressed on the protein 
level in stellate-shaped SMA+ cells of the fibrous cap, whereas expression was still 
detectable on the transcript level in situ, as previously reported by others24. Together, these 
observations highlight the problem of correct SMC identification with respect to our 
understanding of human disease. Other studies seeking to establish the earliest 
determinants of SMC phenotypic switch have shown that e.g. mitochondrial fragmentation 
represents an early mark of SMC activation25. Currently, changes in histone modifications, 
novel SMC-enriched transcription factors such as TCF21 and TET226-29 and epigenetic 
regulation of SMC phenotype by noncoding RNAs30 are also being intensively investigated. 
Nevertheless, our study highlights that we have not yet fully explored the transcriptomic 
landscape in relation to the plethora of SMC phenotypes and adds to elucidation of molecular 
signatures that characterize their plasticity.  
Here, we confirmed that muscle-contraction, muscle-development and acto-myosin 
cytoskeleton were some of the most repressed categories in atherosclerotic tissue, including 
typical markers of SMCs as well as a number of genes previously poorly characterised in the 
context of SMC function. Synemin (SYNM) is an intermediate filament protein whose 
knockdown in saphenous vein SMCs in vitro leads to increased collagen production, 
downregulation of typical SMC markers and disassembly of actin fibers31. Phospholamban 
(PLN) was previously immunolocalized to the nuclear envelope and sarcoplasmic reticulum 
of cardiac SMCs, where it has been proposed to regulate intracellular and intranuclear Ca2+ 
levels32. It has also been shown that Ca2+ signaling pathways are altered in synthetic 
vascular SMCs, which possibly occurs in conjunction with PLN translocation from the 
nucleus to the other subcellular compartments. In a recent study, PLN mutations were linked 
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to dilated cardiomyopathy, ventricular arrhythmias and interstitial fibrosis33. Nanda V et al.34 
described Leiomodin 1 (LMOD1) as a new SMC-restricted, myofilament-related, 
SRF/MYOCD target gene enriched in SMCs in embryonic and adult mouse tissues. Earlier, 
LMOD1 was predicted to belong to a ‘gene battery’ involved in SMC differentiation by a 
bioinformatics screen for regulators of conserved functional gene modules in mammals35. 
Interestingly, Synaptopodin (SYNPO) and PDLIM proteins have been discovered as neuronal 
components and also investigated as adaptor molecules orchestrating actin-cytoskeletal 
organization in foot processes of podocytes36-39, but sparsely linked to SMCs40-43. Apart from 
these few publications, limited information exists about these genes in the literature up to 
date, and to the best of our knowledge, this study is the first to systematically examine their 
implication in human atherosclerosis and vascular remodelling.  
SMCs are currently considered to be the main cell type responsible for intimal repair after 
balloon injury in the rat carotid artery, although cells of mesenchymal origin may also 
contribute 44. In this model, intimal hyperplasia develops in three major stages45, 46 with initial 
SMC activation, replication and beginning of migration to the luminal surface during the first 
two days after injury. Between days two and five, SMCs colonise the intimal surface following 
activity related to chemoattractants and ECM degradation. In the next few weeks, the 
number of SMCs in the neointima continues to increase, but from one month after injury, 
SMC proliferation ceases, the cells become quiescent and regain ultrastructural features 
typical for the contractile state46. Our results show that expression profiles for both typical 
SMC markers and for Synm, Pln, Lmod1, Synpo2 and Pdlim7 reflect these stages by gradual 
downregulation until five days after injury, followed by subsequent upregulation later as 
SMCs become quiescent and regain contractile features. In a similar fashion, 
immunohistochemical staining for typical SMC markers as well as for SYNM, PLN, LMOD1, 
SYNPO2, and PDLIM7 was detected in human intimal hyperplasia, especially in large PCNA- 
areas. Based on these results we hypothesize that SYNM, PLN, LMOD1, SYNPO2, and 
PDLIM7 functionally relate to the phenotypic state of SMCs.   
Freshly isolated rat aortic SMCs seeded on fibronectin and cultured under serum-free 
conditions have previously been used to study the subcellular properties related to SMC 
phenotypic modulation in vitro. Under these conditions, interactions between fibronectin, 
integrin α5β1 and FAK-dependent intracellular signalling promote cell cycle entry and 
dedifferentiation into a synthetic state, accompanied by structural reorganisation and loss of 
myofilaments19, 47, 48. Here, we observed that Synm, Pln, Lmod1, Synpo2 and Pdlim7 (as well 
as Acta2, Myocd, Myh11) were indeed downregulated in primary rat SMCs during the first 
days of culture on fibronectin, but reexpressed from about 5 days of culture, suggesting that 
SMCs retain their inherent plasticity in vitro. Several of the examined genes were localised to 
the actin cytoskeleton in human SMCs implying that they may be involved in reorganisation 
of cytoskeletal structures. Interestingly, while plasticity of SMCs and re-expression of target 
genes and proteins was apparent in human and rat intimal hyperplasia, expression of the 
proteins remained repressed in stellate-shaped SMA+ cells of the fibrous cap in carotid 
plaques. s discussed, this may either be due to a heterogeneous population of cells 
expressing SMA5, 6 or repression of these genes in SMCs by disease specific factors such as 
inflammatory-, apoptotic-, or lipid mediators.   
Therefore, in order to explore whether dominant processes in the atherosclerotic 
environment and in vascular disease in general may influence the genes of interest in our 
study, we investigated the expression of SYNM, PLN, PDLIM7, LMOD1 and SYNPO2 as well 
as other typical SMC markers in SMCs exposed to disease-associated stimuli in vitro. To 
summarize, while we have not yet fully dissected which specific stimulus or combination of 
stimuli may repress expression of SYNM, PLN, PDLIM7, LMOD1 and SYNPO2 in 
atherosclerosis and vascular remodelling, we showed that they were downregulated by 
inflammatory stimuli and cholesterol-uptake, and in response to shear stress (and apoptosis). 
In support of these observations, exposure to lipids has previously been associated with 
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dramatic effects on SMC phenotype and transdifferation into CD68+ macrophage-like foam 
cells, as also demonstrated in our study 20.  
Intima–media thickness of extracranial carotid arteries, measured by ultrasound is a 
commonly accepted non-invasive marker of subclinical atherosclerosis. Several studies have 
established that cIMT changes over time are associated with vascular risk factors22 and 
prediction of vascular events both in subjects with plaques at baseline and in those without. 
Here, genetic variants in PDLIM7, SYNPO2 and PLN showed association with cIMT 
measurements, suggesting that these genes could have a causal role in carotid disease. Of 
note, SYNPO2 variants were located in the intron of the USP53 gene and marginally linked 
to expression in BiKE atherosclerotic plaques. USP53 (Ubiquitin Specific Peptidase 53) is a 
poorly studied protein, highly expressed in the heart muscle and found to be genetically 
associated with the Cantu syndrome, a rare condition characterized clinically by 
hypertrichosis, cardiomegaly and bone abnormalities49. Of particular interest, PDLIM7 SNPs 
linked to fastest-IMTmax-progression were shown to influence expression of PDLIM7 in 
plaques and predicted to constitute binding sites for transcription factors previously 
implicated in cardiovascular development, SMC migration, and SMC proliferation in response 
to cytokine stimulation50, 51. One of these SNPs was positioned in the intronic region of the 
RGS14 gene, and interestingly, the expression of RGS14 also strongly correlated with the 
expression of PDLIM7 in plaques. RGS14 has been shown to act as a positive modulator of 
microtubule polymerisation and spindle organization during cell division by integrating G 
protein and MAPK signaling pathways52, 53. It inhibits PDGF-stimulated ERK1/ERK2 
phosphorylation and may indirectly interact with PDLIM7 via the actin-cytoskeleton.  
The importance of PDLIM7 for SMC phenotype was confirmed by silencing experiments that 
resulted in perturbed cytoskeletal structure, adhesion and spreading as well as SMC 
proliferation. Previous studies in other cell types have shown similar effects of PDLIM7 
knock-down on proliferation (i.e. periodontal ligaments54) and studies of other PDLIM family 
members have shown that they can directly interact with actin-cytoskeleton proteins such as 
α-actinin-4 to stabilise actin fibres39. Similarly, missense mutations of ACTA2 in humans are 
associated with diminished gene expression, defective actin-filaments and actin-based 
spreading in SMCs, and formation of occlusive lesions due to increased SMC proliferation 
and intimal hyperplasia55, 56. Overall, our findings suggest an important structural and 
mechanistic role for PDLIM7 in SMCs, with possible genetic influence on disease 
development.   
Because the BiKE cohort comprises only late-stage lesions and cannot provide information 
about gene expression variations during atheroprogression, expression data was 
complemented with immunohistochemistry on aortic lesions collected from different stages of 
atherosclerotic disease. Of note, PCNA that was used as a proliferation marker in the 
immunohistochemical analysis, has been reported to overestimate the number of replicating 
cells. Consensus is lacking regarding the selection of appropriate control tissues, and in the 
BiKE study, control vessels contained outer media that is not included in the endarterectomy 
samples. Furthermore, the discovery approach in our study was based on microarrays and 
the complexity of microarray data was reduced by pathway analyses and construction of 
functional networks where genes were clustered based on biological functions or protein 
interactions. While this method is limited to semantic mining of existing knowledge from 
published literature and databases, it still permits for discovery of poorly explored genes in a 
certain context.  
In conclusion, using a systems biology approach by integrating transcriptomic, in situ, in vivo, 
in vitro and genetic studies we were able to overcome these limitations and discover several 
novel candidates that demarcate early phenotypic modulation of SMCs in vascular disease. 
In perspective, the full knowledge of key expression signatures is likely to help us derive a 
better definition of various SMC phenotypes that coexist in the vessel wall, and provide 
potential targets for prevention and therapy in vascular disease.   
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Significance  
A large biobank of carotid endarterectomies obtained from patients undergoing surgery for 
symptomatic or asymptomatic carotid stenosis was utilized to uncover genes and 
mechanisms repressed in atherosclerosis. Results demonstrated enrichment of molecular 
pathways related to smooth muscle cell (SMC) function and identified a panel of 
downregulated SMC genes previously not associated with vascular disease. These genes 
(SYNPO2, SYNM, LMOD1, PDLIM7 and PLN) were related to the SMC cytoskeleton, they 
were transiently downregulated during neointima formation after rat carotid balloon injury, 
and polymorphisms in PDLIM7, PLN and SYNPO2 were associated with surrogate markers 
of atherosclerosis in high-risk subjects without symptoms of cardiovascular disease. Our 
work emphasizes the significance of SMC phenotypic modulation in atherosclerosis. In 
addition, these newly described SMC genes may improve definition of the phenotypic state of 
these cells in vascular disease and may be related to the capacity of SMCs to contribute to 
stabilizing processes in atherosclerotic lesions. 
 
Highlights 
• An integrative approach utilizing large biobanks of carotid endarterectomies from 
patients undergoing surgery for symptomatic or asymptomatic stenosis was utilized to 
uncover mechanisms repressed in atherosclerosis. 
• A combination of transcriptomic and proteomic profiling revealed that SMCs related 
molecular categories were the most downregulated in plaques and identified five 
genes previously not associated with atherosclerosis. 
• SYNPO2, SYNM, LMOD1, PDLIM7 and PLN were related to SMC cytoskeleton, 
transiently downregulated during neointima formation after rat carotid balloon injury, 
by PDGFB and IFNg, exposure to shear flow stress and oxLDL loading.  
• Polymorphisms in PDLIM7 were associated with surrogate markers of atherosclerosis 
in high-risk subjects, while it’s silencing in vitro led to downregulation of SMC markers, 
disruption of the actin cytoskeleton, decreased cell spreading and increased 
proliferation. 
• The newly described SMC genes may improve definition of the phenotypic state of 
these cells in vascular disease and relate to their capacity to contribute to stabilizing 
processes in atherosclerotic lesions. 
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Figure Legends 
 
Figure 1. LMOD1, SYNPO2, SYNM, PDLIM7 and PLN were downregulated in carotid 
plaques. Microarray profiles comparing n=127 carotid plaques vs. n=10 normal arteries were 
used in discovery phase for analysis of downregulated genes and pathways. Arroweads 
showing SMA+ smooth muscle cells (SMCs) in the media of normal artery, remaining media 
at the plaque periphery and fibrous cap. Images were taken with 4x objective. (A). Co-
expression and co-interaction network of genes clusterred in pathways ’muscle contraction’, 
’muscle development’, ’actin cytoskeleton’ and ’myofibril cytoskeleton’ shows the presence of 
typical markers of SMCs in these categories (i.e. CNN1, SMTN, TAGLN, ACTA2, MYH11) as 
well as other potentially interesting genes of which some were selected for further 
investigations. Network weighted for closeness in biological function based on publically 
available data (B).  PDLIM7, LMOD1, SYNPO 2, SYNM and PLN were among the most 
downregulated genes in microarrays from plaques (CP) vs. normal arteries (NA) and 
symptomatic (S) vs. asymptomatic (AS) patients (C) and strongly correlated to standard 
markers of SMCs (D). Plots showing log mean±standard deviation in C and Pearson 
correlations in D.  
Figure 2. Selected candidates were localised to differentiated smooth muscle cells and 
reduced in late-stage plaques. By immunohistochemistry, Myh11 (red) was present only in 
normal carotid arteries while Calponin (red) and SMA (green) were detectable in normal 
arteries, in plaques as well as in human intimal hyperplasia tissue with large PCNA- areas 
(arrowheads, A). The identified SMCs markers (red) were all localised to SMCs in the normal 
carotid artery (left column panels, insets show higher magnification). Pdlim7 and Synm were 
also present in subintimal SMA+ cells at the plaque periphery and Pdlim7 was the only one 
still detectable in SMA+ cells in the fibrous cap. Signal for Lmod1, Synpo2 and Pln was lost 
in plaques. Abundant staning for Pdlim7 and Synm was seen in restenosis tissues, and 
Synpo2, Lmod1 and Pln were also observed in PCNA- areas (B).  Images were taken with 
10x objective, insets show 40x magnification.  
Figure 3. Expression of LMOD1, SYNPO2, SYNM, PLN and PDLIM7 strongly correlated 
to typical markers of SMCs during the course of rat carotid artery injury and healing 
response. By microarray profiling, the identified SMC proteins and typical markers of SMCs 
were downregulated in early phases up to day 5 after vessel injury and gradually upregulated 
in later phases in intimal hyperplasia after rat carotid balloon injury (A, B). Expression 
correlations of LMOD1, SYNPO2, SYNM, PLN and PDLIM7 with typical SMCs markers were 
significant and strongly positive in this model (mostly Pearson r>0.8), while they were 
negative with PDGFB, IGF1 and TGFB1 (C).  
Figure 4. Lmod1, Synpo2, Synm, Pln and Pdlim7 were localised to SMCs in intact rat 
carotid artery and reduced in response to injury. By IHC the loss of Calponin (red) from 
highly proliferative PCNA+ SMCs layers in the injured rat artery closer to the lumen was 
observed (arrowheads), while staining was still present in deeper medial layers at day 5. At 
12 weeks after injury Calponin was again abundant in the mature intima with less 
proliferative cells in the deeper layers but absent from luminal PCNA+ layers (arrowheads, 
A). The signal for identified SMCs markers (red) was completely absent at day 5 with gradual 
reappearance from the medial SMCs in tissues with pronounced intimal hyperplasia at 12 
weeks after injury (B). Images were taken with 20x objective, insets show higher 
magnification (100x) of the media.  
Figure 5. LMOD1, SYNPO2, SYNM, PLN and PDLIM7 were expressed by differentiated 
SMCs in vitro and localised to actin cytoskeleton. By flow cytometry 90% of the primary 
rat aortic cells were SMA+ on day 0 (after overnight collagenase treatment, top panel, A) as 
well as 7 days upon isolation when cultured in serum-free medium (second panel from top, 
A). A subpopulation of cells with lower SMA+ signal was identified in cultures at day 0, as 
well as 7 days upon isolation when stimulated with PDGFB (arrows, top and third panel, A). 
Bottom panel in A shows overlap of the upper 3 panels indicating the change in the SMA 
signal during 7 days of culture. By qPCR analysis rSMCs showed downregulation of 
Fo
r A
TV
B P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
. D
es
tro
y
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aft
er 
us
e.
Markers of smooth muscle cells                                                                                                                                                Perisic et al. 
 19
conventional and identified SMCs markers at day 3 upon isolation and a trend towards 
upregulation after 5 days in culture. Graphs showing mean fold change ± SEM, ANOVA p-
values, results representative of 3 independent primary cell isolations (B). In low-passage 
primary human carotid SMCs Pdlim7, Synm and Synpo2 colocalised with the actin 
cytoskeleton (as shown by phalloidin staining in red), Pln showed nuclear localisation and the 
signal for Lmod1 was beyond detection. For comparison, Calponin was localised to actin 
cytoskeleton (C). Images were taken with 100x objective. 
Figure 6. SMCs markers were downregulated in relation to inflammation, lipid-loading 
and hemodynamic stress. CNN1, PDLIM7, LMOD1, SYNPO2, PLN and SYNM were 
rapidly downregulated by IFNg treatment of cultured human carotid SMCs (A) and 
stimulation with oxLDL similarly resulted in downregulation of these genes (B). These SMC 
genes were also repressed in primary rat aortic SMCs by exposure to laminar shear stress 
(dataset GEO accession nr GSE19909, C). Plots show mean fold change ± SEM, p-values 
from T-test or ANOVA when appropriate. Results are representative of 3 independent  
experiments. 
Figure 7. Polymorphism in the PDLIM7 genomic region associated with carotid intima-
media thickness affects its expression in plaque tissue. By eQTL analysis variant 
rs4075958 was associated with the mRNA expression of both PDLIM7 and RGS14 in plaque 
tissue (A, B) and the expression levels of these two genes were strongly correlated (C).  
Functional network coupling based on protein-protein interactions links Pdlim7 and Rgs14 via 
actin cytoskeleton proteins (D). Plots in A and B show median with minimum and maximum. 
Figure 8. Silencing of PDLIM7 leads to downregulation of other SMC markers and 
increased SMC proliferation. PDLIM7 expression was silenced in human SMCs in vitro 
using siRNA (Crystal Violet staining, A), which resulted in downregulation of several other 
SMC markers (B), increased cell proliferation (as evaluated by BrdU incorporation) and 
impaired cell spreading/adhesion ability (C). Plots show mean ± SEM.  
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